

What This Longevity Investor Knows That You Don't | Karl Pfleger, Founder of AgingBiotech.info, Co-Hosted with Dr. Greg Bailey, Chairman of Juvenescence
Jul 5, 2024
Karl Pfleger, founder of AgingBiotech.info and a former Google researcher, dives deep into the rapidly evolving longevity biotech landscape. He discusses the lucrative opportunities in aging-related investments, highlighting how targeting aging could revolutionize health care. Pfleger stresses the importance of understanding mechanisms of action and shares his investment strategies. He also emphasizes the promise of senolytics, or senescent cell clearance, as a leading frontier. For aspiring investors, he recommends diving into conferences and varied resources for informed decisions.
AI Snips
Chapters
Books
Transcript
Episode notes
Prefer Structured Data Over Prose
- Use sortable tables to compare companies by trial stage, modality, and subfield.
- Prefer structured datasets over prose to speed diligence and cross-comparisons.
From Google To Building AgingBiotech.info
- Karl left a decade at Google and moved into aging via philanthropy, then investing.
- He built agingbiotech.info to share his company list and structured data after finding his list far larger than public roundups.
Aging Is Modifiable, Not An Unchangeable Clock
- Aging is a malleable biological process that can be slowed or reversed.
- Treating underlying aging mechanisms could prevent many major chronic diseases before they appear.